Prevention of Relapse & Recurrence of Bipolar Depression

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

177 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-01

Study Completion Date

2016-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether the long-term use of combined antidepressant plus mood stabilizer therapy is superior to mood stabilizer therapy alone in preventing the relapse and recurrence of bipolar depression.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Relapse Prevention for Bipolar Type-II Disorder

NCT00044616

Bipolar Disorder Depression

COMPLETED PHASE4

Antidepressant Therapy in Treating Bipolar Type II Major Depression

NCT00602537

Bipolar Disorder Depression

COMPLETED PHASE4

Antidepressant Therapy for Bipolar II Major Depression

NCT00641927

Bipolar Type II Disorder

COMPLETED PHASE4

Bipolar II Depression: Lithium, SSRI, or the Combination

NCT00276965

Bipolar Disorder Depression

COMPLETED PHASE3

Simvastatin Augmentation of Lithium Treatment in Bipolar Depression

NCT01665950

Bipolar Disorder

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Recurrence of Bipolar I (BP I) major depressive episode (MDE), is now recognized as a major mental health problem. Recurrent BP I MDE is a disorder with no satisfactory therapy, and its treatment remains a challenge to clinicians. To date, initial and long-term therapy of BP I MDE has been based on un-validated practice guidelines. These guidelines recommend limiting antidepressant drug (AD) use during initial therapy of BP I MDE, and completely avoiding AD use during long-term therapy. There is, however, no empirical evidence to suggest that mood stabilizer (MS) monotherapy is superior to combined MS plus AD therapy in preventing recurrent BP I MDE. Nor is there evidence to suggest that long-term MS plus AD therapy results in more manic switch episodes. We present evidence that AD-induced mania during long-term therapy of BP I MDE has been over-estimated, and that long-term use of MS plus AD therapy may be superior to MS therapy alone in preventing recurrent BP I MDE. In this study, we will ask: "Does continuation therapy with combined lithium plus fluoxetine result in fewer MDE relapses and recurrences vs. lithium monotherapy?" To answer this question, patients with BP I MDE will receive combined lithium plus fluoxetine therapy for 8 weeks. Responders who stay well for an additional 4 weeks of consolidation therapy will then be randomized to double-blind continuation therapy with either (i) combined lithium plus fluoxetine, or (ii) lithium alone (following fluoxetine taper and discontinuation) for an additional 50 weeks. We hypothesize that long-term lithium plus fluoxetine therapy will result in fewer MDE relapses and recurrences vs. lithium monotherapy. We will also ask: "What is the relative safety, tolerability, and frequency of syndromal and sub-syndromal manic, hypomanic, and mixed state conversions during continuation treatment with combined lithium plus fluoxetine vs. lithium monotherapy?" To answer this question, we will measure: the frequency, severity, and duration of syndromal and sub-syndromal manic, hypomanic, and mixed state conversions; frequency, severity, and duration of treatment-emergent adverse events; frequency of treatment discontinuation; time to onset of first syndromal and sub-syndromal conversion event; time to first treatment intervention of each syndromal and sub-syndromal conversion event; and, time to onset of increase in suicidal ideation event. We hypothesize that lithium plus fluoxetine therapy will result in a similar frequency of syndromal and sub-syndromal conversion events, and a similar frequency of treatment-emergent adverse events. We further hypothesize that lithium plus fluoxetine therapy will result in fewer suicide ideation events and fewer study discontinuations vs. lithium monotherapy. We believe that the results of this trial may have an important public health impact on the current practice guidelines for treating BP I MDE.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bipolar Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lithium plus Fluoxetine Phase I

All participants were started in this arm. Those who met criteria for entry into Phase II were then randomized to one of the two Phase II arms.

Group Type OTHER

Lithium / Fluoxetine

Intervention Type DRUG

Individualized Daily Dosage

Lithium plus Placebo Phase I

No participants began their participation on Lithium plus Placebo.

Group Type OTHER

Lithium / Placebo

Intervention Type DRUG

Individualized Daily Dosage

Lithium plus Fluoxetine Phase II

Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to continue on both compounds.

Group Type EXPERIMENTAL

Lithium / Fluoxetine

Intervention Type DRUG

Individualized Daily Dosage

Lithium plus Placebo Phase II

Patients who responded to Lithium plus Fluoxetine in Phase I and were randomized to switch from Fluoxetine to placebo.

Group Type PLACEBO_COMPARATOR

Lithium / Placebo

Intervention Type DRUG

Individualized Daily Dosage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lithium / Fluoxetine

Individualized Daily Dosage

Intervention Type DRUG

Lithium / Placebo

Individualized Daily Dosage

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lithium Carbonate / Prozac Lithium Carbonate / Sugar Pill

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men/women (all races and ethnicity)
* Age at least 18 years old
* Bipolar Type I Disorder
* Current Major Depressive Episode
* Able to understand and provide signed informed consent

Exclusion Criteria

* Current alcohol or drug abuse
* Alcohol or drug dependence within 3 months
* Allergic to Fluoxetine or Lithium
* Unstable medical condition (e.g., uncontrolled thyroid, renal, cardiovascular disease)
* Pregnant or nursing women
* Women of child-bearing potential unwilling to use a medically acceptable form of contraception
* Actively suicidal
* Requiring hospitalization
* Use of medication contraindicated with lithium or fluoxetine
* Unable to participate in a year-long trial

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No